RT Journal Article
T1 Follow-up care over 12 months of patients with prostate cancer in Spain A multicenter prospective cohort study
A1 Bonfill, Xavier
A1 Martinez-Zapata, Maria Jose
A1 Vernooij, Robin W. M.
A1 Sanchez, Maria Jose
A1 Morales-Suarez-Varela, Maria
A1 Emparanza, Jose Ignacio
A1 Ferrer, Montse
A1 Pijoan, Jose Ignacio
A1 Palou, Joan
A1 Madrid, Eva
A1 Abraira, Victor
A1 Zamora, Javier
A1 EMPARO-CU Study Grp, 
K1 hormone therapy
K1 multicenter study
K1 multivariate analysis
K1 prostate cancer
K1 prostatic neoplasms
K1 radiotherapy
K1 surgery
AB The therapeutic approach is crucial to prostate cancer prognosis. We describe treatments and outcomes for a Spanish cohort of patients with prostate cancer during the first 12 months after diagnosis and identify the factors that influenced the treatment they received. This multicenter prospective cohort study included patients with prostate cancer followed up for 12 months after diagnosis. Treatment was stratified by factors such as hospital, age group (= 70 years), and D'Amico cancer risk classification. The outcomes were Eastern Cooperative Oncology Group (ECOG) performance status, adverse events (AEs), and mortality. The patient characteristics associated with the different treatment modalities were analyzed using multivariate logistic regression. We included 470 men from 7 Spanish tertiary hospitals (mean (standard deviation) age 67.8 (7.6) years), 373 (79.4%) of which received treatment (alone or in combination) as follows: surgery (n = 163; 34.7%); radiotherapy (RT) (n = 149; 31.7%); and hormone therapy (HT) (n = 142; 30.2%). The remaining patients (n = 97) were allocated to no treatment, that is, watchful waiting (14.0%) or active surveillance (5.7%). HT was the most frequently administered treatment during follow-up and RT plus HT was the most common therapeutic combination. Surgery was more frequent in patients aged = 70 with histologic tumor grade 4, and higher ECOG scores. HT was more frequent in patients aged >= 70, with histologic tumor grades 3 to 4, Gleason score >= 8, ECOG >= 1, and higher prostate-specific antigen levels. The number of fully active patients (ECOG score 0) decreased significantly during follow-up, from 75.3% at diagnosis to 65.1% at 12 months (P = 70, with histologic tumor grades 3 to 4, Gleason score >= 8, ECOG >= 1, and higher prostate-specific antigen levels. The number of fully active patients (ECOG score 0) decreased significantly during follow-up, from 75.3% at diagnosis to 65.1% at 12 months (P = 8, ECOG >= 1, and higher prostate-specific antigen levels. The number of fully active patients (ECOG score 0) decreased significantly during follow-up, from 75.3% at diagnosis to 65.1% at 12 months (P = 1, and higher prostate-specific antigen levels. The number of fully active patients (ECOG score 0) decreased significantly during follow-up, from 75.3% at diagnosis to 65.1% at 12 months (P
PB Lippincott williams & wilkins
SN 0025-7974
YR 2021
FD 2021-11-24
LK https://hdl.handle.net/10668/24666
UL https://hdl.handle.net/10668/24666
LA en
DS RISalud
RD Apr 11, 2025